Evaluation of cefotetan in uncomplicated gonorrhea.
Cefotetan is a newly developed cephamycin especially resistant to bacterial beta-lactamase. Therefore both its in vitro activity against Neisseria gonorrhoeae and its clinical efficacy in uncomplicated gonorrhea are investigated. The minimal inhibitory concentrations (MIC) lie in the range of 0.016-2 micrograms/ml, 90% of the strains being inhibited by 0.5 microgram/ml. Of 52 finally evaluable patients who were treated by a single intramuscular injection of 1 g, 48 (92.3%) were cured bacteriologically. Thus the present treatment protocol may prove useful in individual cases. It should, however, not be advocated for gonorrhea treatment in general.
D000328:Adult; D002439:Cefotaxime / Q000031:analogs & derivatives / Q000627:therapeutic use; D015313:Cefotetan; D015296:Ceftizoxime; D002513:Cephamycins / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D010400:Penicillin G / Q000627:therapeutic use
D002513:Cephamycins; D015313:Cefotetan; D015296:Ceftizoxime; D002439:Cefotaxime; D010400:Penicillin G